Physician profile
Casey Mraz
NPI 1659728855
$2,782.96
in general payments reported to CMS, 2019-2025
20 companies · $29.83 in 2025
The $29.83 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $403 · 2021: $649 · 2022: $609 · 2023: $516 · 2024: $365 · 2025: $29.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $718.63 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $308.97 | 2020-2024 | Ozempic, Rybelsus, Saxenda |
| Pfizer INC. | $301.79 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $292.74 | 2019-2024 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $244.19 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.82 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $146.40 | 2019-2022 | |
| Stryker Corporation | $134.90 | 2022 | |
| Astellas Pharma US INC | $78.44 | 2021-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.44 | 2021-2024 | Xifaxan |
| Amgen INC. | $64.52 | 2019-2024 | Otezla, Repatha, Prolia |
| Merck Sharp & Dohme LLC | $44.66 | 2019-2020 | |
| Abbvie INC. | $42.01 | 2019-2022 | |
| Exact Sciences Corporation | $40.91 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $30.25 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $29.78 | 2019 | |
| Abbott Laboratories | $22.70 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.45 | 2022 | |
| Radius Health, INC. | $14.71 | 2019 | |
| Gilead Sciences, INC. | $14.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Mraz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.